US to Ireland: "We Need Guidance"

Innovating American Manufacturing: Lessons from Ireland’s Rise in Pharmaceutical Production

Image from: Pfizer Healthcare Ireland Unlimited Company. (n.d.). Pfizer Ireland careers. Retrieved May 10, 2025, from https://www.pfizer.ie/pfizer-ireland-careers

Introduction

The evolution of global trade—championed by leaders like Presidents John F. Kennedy and Ronald Reagan—has shaped the United States into a central actor in international commerce. Through global trade relations, the U.S. has successfully emerged from economic downturns, expanded its innovation pipeline, and increased its footprint in global markets. American businesses have strategically leveraged international regions rich in labor and resources to maximize capital efficiency, scale production, and drive innovation. This strategy—fueled by factors such as global educational collaboration, cost-effective labor, favorable trade balances, and corporate tax shelters—has historically contributed to the acceleration of American exceptionalism.

Notably, globalization has reshaped the pharmaceutical manufacturing landscape. Countries like Germany, Switzerland, and especially Ireland have emerged as leading exporters of pharmaceutical goods. Ireland, in particular, has positioned itself as a global manufacturing hub, with companies like Pfizer locating nearly two-thirds of their supply chain operations within its borders. As the U.S. seeks to reclaim leadership in pharmaceutical production, it is essential to analyze the factors enabling innovation and scalable output in a globally competitive environment. Historical examples, including strategic applications of quantitative easing, tax reform, education investment, and open trade models, suggest that with deliberate planning, the United States can regain its stature as the premier pharmaceutical manufacturing nation.

Economic Foundations for Innovation

A nation’s manufacturing leadership is deeply tied to its economic posture. Nations alternate between periods of quantitative easing and tightening—policies that respectively facilitate or restrict capital flow. In times of easing, lowered borrowing costs, increased R&D investment, expanded labor forces, and government-backed trade incentives stimulate production and innovation. Conversely, tightening cycles reduce spending and risk tolerance, hindering growth.

For the U.S. to compete with Ireland and others, it must align with a market cycle conducive to expansion. Historical precedent reinforces this: President Kennedy’s support for global trade following the 1958 recession revitalized foreign investment. Similarly, President Reagan’s economic policies—marked by widespread tax cuts, deregulation, and expanded business spending—catalyzed one of the most significant employment and growth periods in modern history. Under Reagan, increased business spending, larger profit margins, reduced unemployment, and lower inflation followed. These cases underscore that strategic investment and economic flexibility are central to regaining global leadership in pharmaceutical manufacturing.

Learning from Ireland: Cultural Cohesion and Work Ethic

Ireland’s pharmaceutical leadership stems from more than economics. Its cultural history of colonial suppression and resource confiscation by British forces fostered a tight-knit, self-reliant national identity. This historical backdrop has yielded a culturally unified and resilient population committed to collective progress. Concepts like "Meitheal" and a strong Christian foundation have contributed to a national ethos centered on diligence, cohesion, and self-determination—traits advantageous for building a globally competitive workforce.

This cultural homogeneity enables swift policy adoption and national alignment around education and workforce priorities. In contrast, the U.S., a diverse cultural mosaic, while rich in innovation, often faces prolonged compromise due to conflicting political and economic ideologies, impeding rapid progress.

Image from: Ireland. Department of Business, Enterprise and Innovation. (2015, December). Innovation 2020: Excellence, Talent, Impact – Ireland's strategy for research and development, science and technology. Department of Business, Enterprise and Innovation. https://www.gov.ie/en/publication/94e8d-innovation-2020/eDeposit Ireland+10gov.ie+10gov.ie+10

Education and Workforce Alignment

Ireland’s educational system is highly structured and standardized. Student performance is based on final exams following semesters of independent study, and academic success is measured through skill acquisition rather than extracurricular involvement. This approach produces graduates with direct, measurable competencies, particularly in STEM fields.

The Irish government actively identifies and supports high-value sectors like biopharma through targeted policies such as Biopharma 4.0, which focuses on cell and gene therapy, manufacturing modernization, and R&D expansion. As a result, roughly 30% of Ireland’s graduates enter STEM fields, compared to 15-20% in the U.S.

Ireland’s integration of universities with industry enhances practical training and employment outcomes. Its geographic size and limited number of higher education institutions (10-20) make it feasible to streamline partnerships with pharmaceutical firms. In contrast, the U.S.’s vast geography and over 4,000 universities complicate coordinated alignment, though regions like the Bay Area and Research Triangle demonstrate its feasibility on a smaller scale.

Policy and Research Investment: A Strategic Model

Ireland’s Innovation 2020 plan exemplifies its commitment to leveraging research for economic advancement. Backed by Science Foundation Ireland (SFI), Enterprise Ireland, and the Irish Research Council, Ireland devotes approximately 10% of its GDP to research and development, with €60 billion in IDA grants allocated annually to innovation projects.

Ireland’s low corporate tax rate of 12.5% continues to attract global firms. By comparison, U.S. corporate taxes have ranged from 21% to 51% over the past five decades, incentivizing offshoring and reducing domestic reinvestment.

SFI funds 12 national Research Centers built on a hub-and-spoke model, integrated with 14 enterprise-led Technology Centers located on university campuses. These centers facilitate collaboration between academia, public institutions, and industry, streamlining the commercialization of new technologies. Additional mechanisms include public procurement programs to encourage technology adoption, open access to scientific publications, and structured knowledge transfer channels.

Health Innovation Hub Ireland (HIHI) exemplifies how cross-sector collaboration can enhance healthcare delivery and reduce costs. Through partnerships between hospitals, startups, and universities, HIHI accelerates the development of medtech solutions, contributing to Ireland’s standing as a hub for healthcare and pharmaceutical innovation.

Image from: Vrogue. (n.d.). How the Ireland healthcare system works. https://www.vrogue.co/post/how-the-ireland-healthcare-system-works-iais-vrogue-co

Toward a U.S. Manufacturing Renaissance

While the U.S. leads in absolute numbers of institutions and scientific output, it lacks the policy cohesion and infrastructural integration found in Ireland. To regain dominance in pharmaceutical manufacturing, the U.S. must:

1. Establish a cultural consensus on the value of education and STEM-based progress.

2. Invest in education reform that emphasizes core competencies over indirect measures.

3. Integrate higher education with pharmaceutical and biotech sectors through regionally tailored models.

4. Align public funding, tax incentives, and regulatory frameworks to stimulate innovation.

Ireland has demonstrated that a small, coordinated system—backed by consistent policy, a unified cultural vision, and deep investment in research infrastructure—can achieve global impact. The U.S. possesses the scale and talent to surpass this model. By adopting best practices from Ireland while adapting them to its own diverse context, America can usher in a new golden age of pharmaceutical innovation and manufacturing leadership.

Citations:

1. Barron's. (2025, April 18). Trump sets pharma tariffs deadline. The fallout for Lilly, Pfizer, other drugmakers. https://www.barrons.com/articles/trump-pharma-tariffs-eli-lilly-pfizer-18c67056

2. RemotePeople. (n.d.). Average salary in Ireland. https://remotepeople.com/countries/ireland/average-salary/

3. BioSpace. (2025, February 26). U.S. biopharmaceuticals contract manufacturing market size to hit USD 7.83 billion by 2033. https://www.biospace.com/press-releases/u-s-biopharmaceuticals-contract-manufacturing-market-size-to-hit-usd-7-83-billion-by-2033

4. Drexel Education Abroad. (2025, January 19). How the US educational system compares to Ireland’s education system. https://studyabroadblog.drexel.edu/2025/01/19/how-the-us-educational-system-compares-to-irelands-education-system/

5. Higher Education Authority. (n.d.). STEM in higher education. https://hea.ie/statistics/data-for-download-and-visualisations/research-info-byte-series/stem-in-higher-education/

6. National Center for Education Statistics. (n.d.). Bachelor's degrees awarded in STEM fields. https://nces.ed.gov/programs/raceindicators/indicator_reg.asp

7. Afterschool Africa. (2023, August 15). Want to work in Ireland? These 5 STEM skills are in high demand. https://www.afterschoolafrica.com/77764/want-to-work-in-ireland-these-5-stem-skills-are-in-high-demand/

8. Pharmaphorum. (2024, November 30). Why Ireland has emerged as Europe’s biopharma hotspot. https://pharmaphorum.com/rd/why-ireland-has-emerged-europes-biopharma-hotspot

9. Genetic Engineering & Biotechnology News. (2024, December 5). NIBRT says Ireland growing as EU biomanufacturing hub. https://www.genengnews.com/topics/bioprocessing/nibrt-says-ireland-growing-as-eu-biomanufacturing-hub/

10. NIBRT. (2024, October 20). Boston Consulting Group and NIBRT announce the Biopharma 4.0 Alliance. https://www.nibrt.ie/boston-consulting-group-and-nibrt-announce-the-biopharma-4-0-alliance/

11. Institute for Research on Higher Education. (n.d.). Ireland: A study of higher education. https://www.gse.upenn.edu/pdf/irhe/ireland.pdf

12. Innopharma Education. (2024, September 10). Why Ireland attracts the top pharmaceutical companies. https://www.innopharmaeducation.com/blog/why-ireland-attracts-the-top-pharmaceutical-companies

13. Datex Corporation. (2024, August 25). Ireland’s crowning glory: A thriving medtech and pharmaceutical industry. https://www.datexcorp.com/irelands-crowning-glory-a-thriving-medtech-and-pharmaceutical-industry/

14. Oxford Global Resources. (2024, July 15). Pharma and biotech lab trends: Ireland as a hub for the life sciences health industry. https://www.oxfordcorp.com/insights/blog/pharma-and-biotech-lab-trends-ireland-as-a-hub-for-the-life-sciences-health-industry/

15. Department of Enterprise, Trade and Employment. (2020). Innovation 2020. https://enterprise.gov.ie/en/publications/publication-files/innovation-2020.pdf

16. IBISWorld. (2024). Brand name pharmaceutical manufacturing in the US. https://www.ibisworld.com/united-states/industry/brand-name-pharmaceutical-manufacturing/487/

17. PhRMA. (2024, October 5). U.S. biopharmaceutical exports support jobs, innovation. https://phrma.org/blog/us-biopharmaceutical-exports-support-jobs-innovation

18. National Center for Biotechnology Information. (2023). Article PMC10148199. https://pmc.ncbi.nlm.nih.gov/articles/PMC10148199/

19. Tradeimex. (2024, June 30). Top pharmaceutical exporters. https://www.tradeimex.in/blogs/top-Pharmaceutical-exporters

20. World Population Review. (2024). Education rankings by country. https://worldpopulationreview.com/country-rankings/education-rankings-by-country

21. The Brimich Group. (2024, May 20). Hub and spoke distribution model. https://www.thebrimichgroup.com/hub-and-spoke-distribution-model/

22. Knowledge Transfer Ireland. (n.d.). National IP Protocol. https://www.knowledgetransferireland.com/ManagingIP/National-IP-Protocol/

23. John F. Kennedy Presidential Library and Museum. (n.d.). John F. Kennedy on the economy and taxes. https://www.jfklibrary.org/learn/about-jfk/jfk-in-history/john-f-kennedy-on-the-economy-and-taxes

24. Investopedia. (n.d.). Reaganomics. https://www.investopedia.com/terms/r/reaganomics.asp

25. Congressional Research Service. (2024). Business-funded R&D in the United States. https://www.congress.gov/crs-product/R48307